PMID First author Title Journal 24557436 Acevedo-Gadea C Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination InternationalWith Oral Topotecan Journal offor Gynecological Recurrent and Cancer Advanced Endometrial Cancer 24947095 Advani SH Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients withIndian advanced J Cancer cancer. 25052451 Agarwal N Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients WithOncologist Metastatic Urothelial Carcinoma 24907635 Aglietta M A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine inAnn chemotherapy-naive Oncol patients with metastatic pancreatic cancer. 24743052 Alrwas A Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxelMelanoma combined Research with -2 and interferon-[alpha] in patients with metastatic . 24405565 Ando Y Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in JapaneseCancer patients Science with advanced solid tumors. 24563479 Angevin E A Phase I/II, Multiple-Dose, Dose-Escalation Study of , an Anti-Interleukin-6 MonoclonalClin Antibody, Cancer Resin Patients with Advanced Solid Tumors 25482239 Ansell SM PD-1 Blockade with in Relapsed or Refractory Hodgkin’s Lymphoma N Eng J Med 24416138 Aparicio J A phase I, dose-finding study of in combination with gemcitabine and radiation therapyPlos in patients One with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study. 24606884 Aruga A Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancerJ Transl Med 24434430 Bauer S Phase I study of panobinostat and in patients with treatment-refractory metastatic gastrointestinalBr J Cancer stromal tumors. 25149088 Becerra CR A phase I dose-escalation study of MEDI-575, a PDGFRα , in adults with advancedCancer solid Chemother tumors. Pharmacol 25142843 Bellmunt J Phase I Study of in Combination With Gemcitabine and Capecitabine for First-Line TreatmentOncologist of Metastatic or Unresectable Renal Cell Carcinoma 24819685 Bendell JC Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 inCancer subjects Chemother with advanced Pharmacol solid tumors. 24173543 Bendell JC Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-likeClin Cancer Res kinase-1 ligand trap, in patients with advanced cancer. 25411085 Bendell JC Phase 1, Open-Label, Dose Escalaon, Safety, and Pharmacokinecs Study of ME-344 as a Single AgentCancer in 24691674 Bendell JC Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-lineInvest New treatment Drugs for patients with metastatic colorectal cancer 24368401 Besse B A phase Ib dose-escalaon study of everolimus combined with cisplan and etoposide as first-lineAnn therap Oncoly in paents with extensive-stage small-cell lung cancer 24685058 Bitting RL A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in PatientsClinical With Genitourinary Advanced Renal Cancer Cell Carcinoma 25327558 Blumenthal GM A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors Oncotarget 23665950 Boku N Phase I study of suninib plus S-1 and cisplan in Japanese paents with advanced or metastac Investgastric New cancer. Drugs 25290091 Brana I A parallel-arm phase I trial of the humanised anti-IGF-1R antibody in combination withB J Cancer the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. 24395457 Britten CD Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patientsInvest with advancedNew Drugs cancer. 25102375 Cabanillas ME A Phase I Study of (XL184) in Patients with Differentiated Thyroid Cancer Thyroid 24942404 Calvo E Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexedInvest New and Drugscisplatin in patients with advanced cancer. 24627219 Chan S A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicinCancer as first-line Chemother treatment Pharmacol in metastatic breast cancer 25577133 Chang TC Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients Cancer Chemother Pharmacol 25312684 Chawla SP A Phase 1B/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma Cancer 25393368 Chen EX A Phase I study of cyclin-dependent kinaseinhibitor , AT7519, in paents with advanced cancer: NCICBr JClinical Cancer Trials Group IND 177 25752751 Cheson BD A phase I study of bendamustine, lenalidomide and in relapsed and refractory lymphomasBr J Haematol 24346101 Chiappori A Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsedJournal non-small-cell of Thoracic Oncology lung cancer. 24711549 Chien AJ Phase I Dose-Escalation Study of 5-Day Intermittent Oral Therapy in Patients With HumanJ Clin Epidermal Oncol Receptor 2–Overexpressing Breast Cancer 24452395 Chiorean EG A phase I study of , an anti-platelet-derived alpha (PDGFRα) monoclonalCancer Chemother antibody, Pharmacol in patients with advanced solid tumors. 25536954 Choy E Phase 1 Study of Oral Abexinostat, a Histone Deacetylase Inhibitor, in Combination With DoxorubicinCancer in Patients With Metastatic Sarcoma 24108668 Ciunci CA Phase 1 and pharmacodynamic trial of everolimus in combination with in patients withCancer advanced cancer. 24916770 Cleary JM A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination withInvest gemcitabine New Drugs in patients with solid tumors. 24983373 Cohen SJ Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheresB J Cancer (SIR-Spheres) in patients with advanced cancer. 25270361 Cohn A A phase I dose-escalaon study to a predefined dose of a transforming growth factor-β1 monoclonalInternational journal of oncology 25403209 Conlon KC Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine productionJ Clin Oncol during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. 24740268 Costello BA Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors Invest New Drugs 25542057 Coupe N PACMEL: A phase 1 dose escalation trial of (GSK1120212) in combination with paclitaxelEur J Cancer 24610297 Curtis KK Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients Cancerwith advanced Chemother LHRH-receptor-expressing Pharmacol solid tumors 25605849 Daud AI Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in CombinationJ Clin Oncol With Gemcitabine in Patients With Advanced Solid Tumors 25025963 Del Conte G Phase I study of olaparib in combinaonwith liposomal doxorubicin in paents with advanced solidBr tumours J Cancer 24262587 Delord JP Open-label, mulcentre expansion cohort to evaluate in pre-treated paents with KRAS-mutantEur J Cancer 25059319 Doi T Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced Cancersolid tumors Chemother Pharmacol 24297161 Dunbar EM Phase 1 trial of dichloroacetate (DCA) in adults with recurrentmalignant brain tumors Invest New Drugs 24563480 Elez ME First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid TumorsClin Cancer Res 24518092 Ellis PM NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combinaon with Cisplan and EtoposideJournal ofin Extensive-StageThoracic Oncology Small-Cell Lung Cancer 24714750 Eskens FA A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxelBr J Cancer in advanced solid tumours 25135998 Fanale MA in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas:J Clin resultsOncol of a phase I study. 25183650 Figg WD A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patientsCancer with refractoryChemother neoplasms. Pharmacol 24615776 Flinn IW Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-d, as therapy for previously treatedBlood indolent non-Hodgkin lymphoma 24141374 Floquet A Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phaseCancer I dose-finding Chemother study. Pharmacol 24306314 Fu S Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advancedInvest malignancies New Drugs 25065668 Fumoleau P A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053The Breast Lapatam study) 25153538 Gadgeel SM Safety and activity of against systemic disease and brain metastases in patients with -resistantLancet Oncol ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-fi nding portion of a phase 1/2 study 25023489 Galsky MD Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatinCancer Chemother in patients Pharmacol with advanced solid tumors 24727324 Galsky MD A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer Clin Cancer Res 24323026 Gandhi L Phase I Study of in Combination With Temsirolimus in Patients With Human Epidermal JGrowth Clin Oncol Factor Receptor 2–Dependent and Other Solid Tumors 23756764 Ganesan P Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.Invest New Drugs 25891174 Garon EB for the Treatment of Non–Small-Cell Lung Cancer N Eng J Med 24271274 Ghamande S A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and Invest New Drugs 24530971 Gopal AK Myeloablativepharmacokinetics I-131- with Escalating Doses of Fludarabine and Autologous HematopoieticBiol Blood Transplantation Marrow Transplant for Adults Age ! 60 Years with B Cell Lymphoma 24429877 Gray JE A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combinedClin Cancer with Res in patients with advanced aerodigestive tract tumors. 24438504 Hagihara A Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion withCancer cisplatin Science for advanced hepatocellular carcinoma. 25615852 Hainsworth JD and Liposomal Doxorubicin in the Treatment of Patients with Relapsed/Refractory EpithelialCancer Ovarian Investigation Cancer: A Phase Ib Study of the Sarah Cannon Research Institute 25086465 Halperin DM A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers BMC Cancer 25533184 Hamberg P Impact of pazopanib on docetaxel exposure: results of a phase I combinaon study with two differentCancer docetaxel Chemother schedu Pharmacolles 24366297 Hamberg P Pazopanib exposure decreases as a result of an ifosfamide-dependent drug drug interaction: Br J Cancer 24989332 Hassan R Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatinCancer for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. 24612787 Hazama S A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastaticJournal colorectal of Translational cancer; safety, Medicine immunological response, and clinical outcome 25750312 Hecht JR Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic ColorectalAnticancer Cancer Res 24456794 Hollebecque A A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimusEur J inCancer patients with solid tumours. 24258465 Hong DS A phase I, open-label, single-arm, dose-escalaon study of E7107, a precursor messenger ribonucleicInvest acid New (pre-mRNA) Drugs 24746841 Hong DS MABp1, a fi rst-in-class true human anbody targeng interleukin-1α in refractory cancers: an open-labelLancet Oncol, phase 1 24365125 Hong DS A Phase I, Open-Label Study of TrebananibCombined With Sorafenib or Suninib in Paents With ClinicalAdvanced Genitourinary Renal Cell Carcinoma Cancer 24752867 Hong DS Dual Inhibion of the Vascular Endothelial GrowthFa ctor Pathway A Phase 1 Trial Evaluang BevacizumabCancer and AZD2171 () in Paents With 24807459 Horinouchi H A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of JapaneseCancer Chemother patients with Pharmacol advanced or metastatic non-small cell lung cancer (NSCLC). 24829073 Ikeda M Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, anInvest oral Newantiangiogenic Drugs agent, and S-1 in patients with advanced hepatocellular carcinoma. 24521523 Ikeda M Japanese phase I study of GC33, a against glypican-3 for advanced hepatocellularCancer carcinoma Sci 24705975 Imbs DC Pharmacokinetics of pazopanib administered in combination with Cancer Chemother Pharmacol 24464355 Inada-Inoue M Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.Cancer Chemother Pharmacol 25262379 Infante JR Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor,Eur in J patients Cancer with refractory solid tumours 25113756 Infante JR Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in PatientsJ Clin With Oncol Advanced Solid Tumors 25057177 Inwards DJ Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaAnn Oncol 24283925 Isambert N How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokineticBr J Clin Pharmacol and tolerability phase I study. 25687990 Ishiwatari H Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliaryCancer tract Chemother cancer. Pharmacol 25202113 Iwahashi S Effects of Valproic Acid in Combination with S-1 on Advanced Pancreatobiliary Tract Cancers: ClinicalAnticancer Study Phases Res I/II 25923549 Jänne PA AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer N Eng J Med 24496004 Jänne PA WeeklyPhase I SafetyEZN-2208 and (PEGylatedPharmacokinec SN-38) Study in combination of the PI3 K/mTORwith bevacizumab Inhibitor SAR245409 in patients with(XL765) in CombinaonJ Thoracic Oncol 24242862 Jeong W refractory solid tumors Invest New Drugs 25287827 Johnson DB Combined BRAF () and MEK Inhibition (Trametinib) in Patients With BRAFV600-MutantJ ClinMelanoma Oncol Experiencing Progression With Single-Agent BRAF Inhibitor 25029236 Joka M Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapyAnti-Cancer for Drugs locally advanced and/or metastatic pancreatic cancer: a dose-finding study. 23959599 Jones JA Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstratesAm J Hematolactivity in relapsed and refractory non-Hodgkin's lymphoma. 25486878 Kang YK A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapyCancer Chemother (GASTANA) Pharmacol 24820348 Kashiwaba M A phase I study of capecitabine combined with CPT-11 in metastatic breast cancer pretreated withOncology anthracyclines and taxanes. 25427841 Kim KP A Phase I Study of UGT1A1 *28/*6 Genotype- Directed Dosing of Irinotecan (CPT-11) in Korean PatientsOncology with Metastatic Colorectal Cancer Receiving FOLFIRI 25349975 Koczywas M Phase I study of the halichondrin B analogueeribuli n mesylate in combinaon with cisplan in advancedBr J Cancer solid tumors 24337768 Komatsu Y Phase 1 study of efatutazone, a novel oral peroxisome proliferator-acvated receptor gamma agonist,Invest in New combinaon Drugs with FOLFIRI as second-line therapy in paents 25271537 Kumar A A phase 1 dose-escalation study of XmAb 2513 in patients with relapsed or refractory Hodgkin lymphomaBr J Haematol 24875132 Kurata T Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel:Invest phase New i Drugsstudy in Japanese patients with advanced solid malignancies and advanced breast cancer. 23979492 Lazar V Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonographyInvest New Drugs and genomic analysis of sequential tumor biopsy samples. 24842883 Lee JM Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarianJ Natl cancerCancer withInst biomarker analyses. 25217393 Li C Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracilCancer and leucovorin Chemother (m-FOLFOX6) Pharmacol in Chinese patients with unresectable liver metastases from colorectal cancer. 24755882 Lin CC A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor,Br J Cancer in patients with advanced solid malignancies. 24708624 Linuma H Phase I clinical study of mulple epitope pepde vaccine combined with chemoradiaon therapyJ in Transl esopha Medgeal cancer paents 24771350 Loriot Y Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patientsInvest withNew metastatic Drugs castration-resistant prostate cancer: multi-centre phase I/II study. 23817974 LoRusso P Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, Investan investigational New Drugs inhibitor of EGFR and HER2. 23903897 LoRusso PM , a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1,Invest New in theDrugs treatment of patients with advanced solid malignancies: a Phase 1 study. 24658629 Lv F Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patientsCancer with Chemother advanced Pharmacol solid tumors 25355819 Maddocks K A phase 1/1b study of rituximab, bendamusne, and ibrunib in paents with untreated and relapsed/refractoryBlood non-Hodgkin lymphoma 24390424 Mahadevan D Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combinationCancer Chemother with multiple Pharmacol standard oncology regimens in patients with advanced solid malignancies. 25304209 Mahalingam D Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patientsCancer with Chemother advanced solid Pharmacol tumors 24316557 Markowitz J A Phase I trial of Bortezomib and Interferon Alfa-2B in MetastacMelanoma J Immunother 23801301 Martin-Liberal J Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a SpanishInvest group New Drugsfor research on sarcomas (GEIS) study. 25003665 Martin-Liberal J Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabineBr in Jpatients Cancer with advanced solid tumours. 25117615 Matsubara N Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistantCancer Sciprostate cancer 24663045 Mayer IA Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide- 3-Kinase Inhibitor Buparlisib With LetrozoleJ Clin Oncol in Estrogen Receptor-Positive/Human Receptor 2-Negative Metastatic Breast Cancer 24819684 McRee AJ A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumabCancer Chemother in patients Pharmacolwith refractory solid tumors. 25556030 Merchan JR Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinomaCancer previously Chemother treated Pharmacol with inhibitors: a phase 2 consortium study 24338555 Misumi Y A Feasibility Study of Carboplatin Plus Irinotecan Treatment for Elderly Patients with Extensive DiseaseJap J Clin Small-cell oncol Lung Cancer 24849582 Mita M Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advancedCancer Chemother solid tumors. Pharmacol 23832397 Mita M A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371ATarget in patients Oncol with solid tumors. 24842548 Mittal K Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamicCancer biomarkers. biology and therapy 24387695 Molife LR Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinibJ in Hematol patients Oncol. with advanced solid tumors. 24190702 Molina AM A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor (E7080) in combinationCancer withChemother everolimus Pharmacol for treatment of metastatic renal cell carcinoma (RCC). 24598448 Monk P A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell CarcinomaJ Immunother and Melanoma 24618589 Morris JC Phase I Study of GC1008 (Fresolimumab): A Human Anti- Transforming Growth Factor-Beta (TGFb)Plos Monoclonal One Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma 25012508 Mross K Vascular effects, efficacy and safety of in patients with advanced, refractory colorectalBMC cancer: Cancer a prospective phase I subanalysis. 25202104 Murakami H Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors. Anticancer Res 24477603 Murakami H An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascularCancer disrupting Chemother agent, Pharmacol administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. 23609829 Naing A Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.Invest New Drugs 25143299 Nakai Y A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancerCancer Chemother Pharmacol 25567350 Newman EM A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitorCancer 5-fluoro-2'-deoxycytidine, Chemother Pharmacol administred with tetrahydrouridine 24782485 Okusaka T Safety, tolerability, pharmacokinetics and antitumor activity of , an investigational fullyJpn human J Clin monoclonal Oncol antibody to -like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study. 25052698 Olivier G A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisoloneAmerican for J ofuntreated Hematology elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial 25146490 Pagel JM (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsedBr orJ Haematol refractory NHL patients. 24965340 Pan E Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brainJ Neurooncol metastases from solid tumors. 23525756 Pant S A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, inInvest patients New with Drugs advanced solid tumors 24633809 Patnaik A A Phase Ib study evaluang MNRP1685A, a fully human an-NRP1 monoclonal anbody, in combinaonCancer Chemother Pharmacol 24901237 Patnaik A Phase I monotherapy or with erlotinib for refractory advanced solid tumours and multipleBr J Cancer myeloma. 25374407 Piatek CI Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors Cancer Chemother Pharmacol 24742900 Piha-Paul SA Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumabOncotarget and the mTOR inhibitor temsirolimus 24674872 Plimack ER A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell CarcinomaOncologist and Soft Tissue Sarcoma 24875133 Plimack ER A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyteInvest New populations. Drugs 24880570 Plummer R Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combinationCancer with temozolomide Chemother Pharmacol in patients with solid tumors. 24908540 PowlesT A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelialEur growth J Cancer factor refractory clear cell renal cancer. 24991839 Rangwala R Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solidAutophagy tumors and melanoma. 24991838 Rangwala R Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimusAutophagy in patients with advanced solid tumors and melanoma. 23539344 Raymond E A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combinationInvest with Newgemcitabine Drugs in patients with solid tumors. 24322542 Reynés G A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrentAnticancer glioblastoma. Drugs 25037139 Ribas A Combinaon of and cobimenib in paents with advanced BRAFV600-mutated melanoma:Lancet aOncol phase 1b study 24132920 Ribrag V A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administeredClin by Cancer intravenous Res infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. 23645447 Richter S A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabineInvest in patients New Drugs with advanced solid tumors (PHL-078/CTEP 8575). 24914044 Rini B A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastaticAnn Oncol renal cell carcinoma. 25034862 Robert C Anti-programmed-death-receptor-1 treatment with pembrolizumab in -refractory advancedLancet melanoma:Oncol a randomised dose-comparison cohort of a phase 1 trial 24652201 Rodon J Phase I dose-escalaon and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitorInvest, inNew paents Drugs with advanced solid tumors 24523439 Rodon J A Phase I, Multicenter, Open-Label, First-in-Human, Dose- Escalation Study of the Oral SmoothenedClin Inhibitor Cancer Res Sonidegib (LDE225) in Patients with Advanced Solid Tumors 23568716 Rubinson DA Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I studyInvest of New Drugs plus cetuximab in cetuximab-refractory patients. 24474568 Rudek MA A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapyCancer in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. 25103371 Saba NF Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and CarboplatinCancer for Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck 24097863 Saif MW A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administeredClin orally Cancer in patients Res with advanced solid tumors. 24744161 Salazar R Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737)Cancer in combination Chemother with Pharmacol docetaxel in patients with advanced solid tumors 24535315 Salazar R Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors 24692743 Sasaki Y Phase I Study of Combination Therapy with Irinotecan, Leucovorin, and Bolus and Continuous-infusionAnticancer 5-Fluorouracil Res (FOLFIRI) for Advanced Colorectal Cancer in Japanese Patients 24480865 Sato D Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamousChemotherapy cell carcinoma. 24470511 Saura C Phase Ib study of Buparlisib plus in patients with HER2-positive advanced or metastaticClin breastCancer cancer Res that has progressed on Trastuzumab-based therapy. 24448638 Sausville E Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabineCancer Chemother in US patients Pharmacol with advanced solid tumors. 23860642 Schelman WR A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors withInvest an expanded New Drugs cohort in extensive-stage small cell lung cancer. 25403217 Schultheis B First-in-Human Phase I Study of the Liposomal RNA Interference Therapeuc Atu027 in Paents WithJ Clin Adva Oncolnced 24166903 Shapiro GI Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-classClin Cancer I PI3K Resinhibitor, in patients with advanced solid tumors. 25377157 Sharma S A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostatCancer Chemother in patients Pharmacol with advanced solid tumors and varying degrees of renal function 24670165 Shaw AT in ALK-Rearranged Non–Small-Cell Lung Cancer N Eng J Med 25264305 Shaw AT Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer N Eng J Med 25107918 Shimizu T Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 inClin Patients Cancer with Res Advanced Solid Tumors 24585045 Shoji T A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (TohokuCancer Gynecologic Chemother CancerPharmacol Unit 104 study) 25253045 Slingerland M A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostatCancer Chemother in patients Pharmacol with advanced solid tumors and various degrees of hepatic function 24770667 Smith DA Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055,Cancer erlotinib, Immunol and Immunother bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. 25327557 Soliman HH A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in paentsOncotarget with metastac 25193991 Soria JC Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanibAnn Oncol in advanced solid tumors 25434923 Spicer J Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFREur and J Cancer HER2, in patients with solid tumours 25625276 Spreafico A A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adultBr patientsJ Cancer with advanced solid malignancies 24024696 Stein A Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophagealActa Oncol cancer: results of a multicenter phase I/II study. 24448640 Stewart CF Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adultsCancer with Chemother refractory Pharmacol solid tumors. 24173967 Strickler JH Phase I study of in combination with capecitabine, oxaliplatin and bevacizumab followedInvest by an New expanded Drugs cohort in previously untreated metastatic colorectal cancer. 23733258 Strieth S Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomeshead neck for targeted therapy in advanced . 23553067 Sunakawa Y in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.Invest New Drugs 25537627 Suzuki K A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostateCancer cancer Chemother Pharmacol 24634378 Tabernero J A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid TumorsClin Cancerand Liver Res Metastases 24688087 Takeoka H Phase I Study of Carboplan Combined with Pemetrexed for Elderly Paents with Advanced Non-squamousJap J Clin oncol Non-small Cell Lung Cancer 24800949 Tan AR Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid Brmalignancies J Cancer 24779747 Terazawa T Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment:BMC a phaseCancer I trial. 23589215 Tjulandin S Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3)Invest signaling, New Drugs in patients with advanced solid tumors. 24674875 Toffalorio F Phase Ib of Sorafenib in Combination With Everolimus in Patients With Advanced Solid Tumors, SelectedOncologist on the Basis of Molecular Targets 24440085 Tolcher A A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.Eur J Cancer 25417902 Tolcher AW Phase I study of the MEK inhibitor tramenib in combinaon with the AKT inhibitor afureserb inCancer paent Chemothers with solid Pharmacol tumors and mulple myeloma 24297683 Tolcher AW A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients Cancerwith advanced Chemother solid Pharmacol tumors 24492162 Tsao AS Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectableClin Lung malignant Cancer pleural mesothelioma. 24586081 Tsimberidou AM Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients With Advanced Cancer J Natl Compr Canc Netw 23665866 Turkington RC A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX)Invest in advancedNew Drugs oesophagogastric adenocarcinoma. 24696229 Ueda T Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as aInvest 24-h continuous New Drugs infusion in Japanese patients with soft tissue sarcoma 25527204 Uronis HE A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advancedCancer solid Chemother tumors Pharmacol 25422155 Uwagawa T Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliaryCancer tract Chemothercancer Pharmacol 25125340 van Iersel LBJ Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastasesEur J Surg confined Oncol to the liver: A phase I study 25037684 Vergote I A phase 1b, open-label study of trebananib in combinaon with paclitaxel and carboplan in paentsEur Jwith Cancer ovarian cancer receiving interval or primary debulking surgery 25019569 Vergote I A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecanGynecol in women Oncol with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. 24894650 Vlahovic G A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxelInvest in the New treatment Drugs of patients with solid tumors. 24458261 Von Mehren M A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjectsInvest with New relapsed Drugs or refractory solid tumors. 24752449 Wakui H A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patientsCancer with advanced Chemother solid Pharmacol tumors 24442032 Wakui H Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targetingCancer HER3, Chemotherin Japanese Pharmacol patients with advanced solid tumors. 25617965 Wang J Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistantClin Exp prostateMetastasis cancer 24916546 Wang-Gillam A A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solidCancer malignancies. Chemother Pharmacol 24604265 Weekes CD A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advancedInvest solid New tumors Drugs 25480557 Weihrauch MR Phase I/III clinical study study of erlotinib of the andtoll-like temsirolimus receptor 9 for agonist patients MGN1703 with recurrent in patients malignant with metastatic gliomas: solidEur tumours J Cancer 24470557 Wen PY North American Brain Tumor Consortium trial 04-02. Neuro oncol 24435060 Wheler JJ Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproicCancer Chemotheracid in patients Pharmacol with advanced cancers 25268371 Wilky BA A phase I trial of vertical inhibition of IGF signalling using , an anti-IGF-1R antibody, Band J Cancer , an MEK 1/2 inhibitor, in advanced solid tumours 23532594 Yamada Y A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastricGastric cancer Cancer 25332421 Yamamoto H Phase I and pharmacokinec study oftrastuzumab emtansine in Japanese paents with HER2-posiveJap J metastac Clin oncol breast cancer 25034977 Yang J Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity andCancer preliminary Chemother efficacy Pharmacol 23712440 Yoo C Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-lineInvest New chemotherapy Drugs in advanced gastric cancer. 25042202 Younes A Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneLancet (R-CHOP) Oncol for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study 24612546 Zhang J A phase I study of AST1306, a novel irreversibleEGF R and HER2 kinase inhibitor, in paents with advanced Journal of solid Hematology tumors & Oncology